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William Matsui,1 Ivan Borrello,1 Constantine Mitsiades2It is well established that high-dose therapy (HDT) combined with autologous stem cell transplantation
(ASCT) produces superior response rates and progression-free survival compared with conventional
chemotherapy in patients with multiple myeloma (MM). Accordingly, MM currently represents the most
common indication for ASCT. Despite these clinical improvements, the impact of ASCTon overall survival
is unclear because the vast majority of patients eventually experience disease relapse and progression. The
continual risk of relapse suggests that malignant cells resistant to HDT possess the clonogenic growth
potential to mediate tumor regrowth, and in several diseases cancer stem cells (CSCs) have been identified
that are both highly tumorigenic and resistant to standard anticancer approaches. Putative CSCs have been
identified in MM, and their characterization may lead to the development of novel maintenance strategies
that inhibit the production of new tumor cells, prevent disease relapse, and improve overall survival.
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ASCT has been considered the standard approach
for frontline therapy in eligible multiple myeloma
(MM) patients based on several randomized trials
comparing ASCT to conventional chemotherapy.
Since 1996, 7 randomized clinical trials have been
reported and clearly demonstrated the superiority of
ASCT in inducing disease responses, especially com-
plete remissions, and prolonging event-free survival.
In contrast, the impact of ASCT on overall survival
(OS) has remained unclear. The IFM90, MRC VII,
and Italian MMSG phase III trials demonstrated
significant prolongation of median OS in newly diag-
nosed patients undergoing ASCT [1-3]. However,
these results are balanced by the PETHEMA,
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OS for patients undergoing ASCT compared with
those receiving conventional chemotherapy [4-7].
Moreover, a recent meta-analysis of 2411 patients
failed to identify a significant OS advantage for
ASCT [8]. The uncertain impact of ASCT on OS is
largely because of disease relapse and progression
that affects virtually all MM patients regardless
of whether or not they have undergone ASCT.
Accordingly, the development of maintenance strate-
gies to prolong responses and improve OS has been
the subject of great interest.MAINTENANCE THERAPY FOR MM IN THE
POSTTRANSPLANT SETTING
Several strategies have been examined in hopes
of extending disease responses following ASCT. Initial
studies focused on the use of interferon-alpha (IFN-a)
based on its ability to improve OS when used as main-
tenance following conventional chemotherapy [9].
Patients with major reductions in tumor burden when
initiating maintenance appeared to gain the greatest
benefit. Therefore, the post-ASCT setting was thought
to represent the optimal time to utilize maintenance
IFN-a, and this concept was supported by a retrospec-
tive European Blood and Marrow Transplant analysis
demonstrating improved progression-free survival
(PFS) and OS in patients receiving IFN-a [10]. Two
randomized studies were subsequently undertaken but
failed to demonstrate improvedOS in patients adminis-
tered IFN-a following ASCT [7,11]. Although better
tolerated post-ASCT than following conventionalS27
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the unclear impact on survival has led to the abandon-
ment of this approach.
The introduction of novel agents including thalid-
omide, its analog lenalidomide, and the proteosome
inhibitor bortezomib over the past decade have
dramatically modified treatment approaches for MM
[12,13]. All of these agents were initially tested and
approved for use in patients with refractory and
relapsed disease, but their relative efficacy has led to
their examination and incorporation into both initial
treatment paradigms as well as in the maintenance
setting following ASCT. Maintenance thalidomide
has been extensively studied, and to date, 5
randomized clinical trials have been reported [7,14-
17]. The IFM 99-02 study compared the use of
thalidomide and pamidronate post-ASCT to pamidro-
nate alone or no maintenance in patients with
standard-risk myeloma [14]. Here, thalidomide dem-
onstrated significantly greater response, PFS, and OS
rates. These results were essentially replicated in a
randomized study from Australia (ALLG MM6) that
compared thalidomide and prednisone with predni-
sone alone [15]. In contrast, 3 other large studies
have failed to demonstrate improvements in OS de-
spite higher response rates and prolonged PFS and
event-free survival. These studies have included Total
Therapy 2, in which patients received thalidomide
both during induction and as maintenance within
a complex regimen that included induction chemo-
therapy, tandem ASCT, and IFN-a and dexametha-
sone post-ASCT [18], the HOVON 50 study
utilizing thalidomide during induction therapy fol-
lowed by thalidomide or interferon as maintenance
[17], and the MRC Myeloma IX trial in which thalid-
omide was administered following either ASCT or
conventional therapy [16]. Although an overview of
these studies fails to provide definitive evidence for
the use of thalidomide as maintenance following
ASCT, distinct groups of MM patients appear to
benefit. In the IFM 99-02 trial, thalidomide mainte-
nance was found to be beneficial in patients failing
to achieve less than a very good partial remission
following ASCT, whereas a subsequent analysis of
Total Therapy 2 at a median follow-up of 72 months
demonstrated a significant improvement in OS in
patients with detectable metaphase cytogenetic ab-
normalities who received thalidomide [19]. Therefore,
it is likely that specific subgroups of MM patients
may benefit from thalidomide maintenance, but this
potential benefit must be weighed against adverse ef-
fects of the drug, most notably cumulative peripheral
neuropathy that is dependent on the dose and duration
of administration.
Data concerning the use of bortezomib and lenali-
domide as maintenance following ASCT are limited
given their more recent approval. The incorporationof bortezomib into both induction and post-ASCT
therapy has been the subject of 2 large randomized
phase III studies in Europe [20,21]. Accrual has been
completed on each of these trials and further follow-
up will better define the utility of bortezomib in the
maintenance setting. Posttransplantation lenalido-
mide is under study in several randomized studies,
and preliminary findings have recently been reported.
In the IFM 2005-02 trial, 614 patients were adminis-
tered lenalidomide as consolidation following ASCT
then randomized to receive maintenance lenalidomide
or placebo [22]. PFS was significantly greater in pa-
tients in the lenalidomide maintenance arm. However,
5-year survival rates for each group was identical at
83%. In the CALGB 100104 trial, 460 patients were
randomized to receive maintenance lenalidomide or
placebo following ASCT [23]. Patients receiving lena-
lidomide experienced significantly prolonged time to
progression, although the impact on OS is less clear
given the low number of deaths. Lenalidomide was
well tolerated in both trials, but an increased incidence
in the rate of secondary malignancies has been ob-
served in each. Therefore, the role of lenalidomide
maintenance following ASCT remains unclear, and
the balance between beneficial effects on MM relapse
and potential toxicity must be further evaluated.CANCER STEM CELLS IN MM
Disease relapse remains the major factor limiting
OS; therefore, a better understanding of the pro-
cesses responsible for tumor recurrence and regrowth
may ultimately lead to improvements in long-term
outcomes. Emerging data in a wide range of human
malignancies, including MM, have demonstrated
that cells within an individual tumor may be pheno-
typically and functionally heterogeneous despite their
clonal origins [24]. The majority of cells appear to
lack sufficient long-term replicative potential re-
quired for disease propagation. Instead, tumor
growth arises from relatively rare populations of phe-
notypically distinct cancer stem cells (CSCs). In both
hematologic malignancies and solid tumors, CSCs
have been prospectively identified based on their
ability to give rise to differentiated progeny that reca-
pitulates the original tumor in the ectopic setting.
Several studies have also found that CSCs are rela-
tively resistant to standard anticancer agents com-
pared with bulk tumor cells. Therefore, CSCs may
play a central role in disease relapse because they
have the ability to persist during treatment and give
rise to new tumor cells.
Several approaches have been undertaken to iden-
tify cancer stem cells [25]. Determination of specific
cell surface antigens expressed by tumorigenic cells
has been most commonly employed, and candidate
markers have consisted of markers characteristic of
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origin (eg, CD34 in myeloid leukemias), expressed
by multiple normal stem cells (eg, CD133 in brain
tumors), or associated with poor prognosis (CD44
in solid tumors). In addition, flow cytometric assays
indicative of drug resistance, such as the Aldefluor
assay that measures aldehyde dehydrogenase activity
or detection of side population cells with increased
drug efflux capabilities, have also been used to isolate
tumor cells with relatively enhanced tumorigenic po-
tential. InMM, each of these strategies has successfully
identified candidate CSCs.
Several studies have examined MM CSCs within
the context of normal plasma cell differentiation. In
a simplistic schema of normal B cell development,
na€ıve B cells harboring immunoglobulin V(D)J gene
rearrangements undergo somatic hypermutation in
germinal center reactions to produce unique antibody
idiotypes and improve antigen binding specificity and
affinity. Germinal center B cells subsequently give
rise to postgerminal center memory B cells that main-
tain long-term humoral immunity and differentiate
into antibody secreting plasma cells upon antigen
reexposure. The examination of immunoglobulin
gene sequences inMMplasma cells have demonstrated
that they are somatically hypermutated and remain
constant throughout the entire clinical course, sug-
gesting that the disease arises from postgerminal cen-
ter memory B cells or plasmablasts [26]. The unique
immunoglobulin gene rearrangement also provides
a highly tumor-specific means of establishing clonal
relationships among different tumor cell populations,
and several studies over the past 2 decades have
detected phenotypic B cells sharing the identical
immunoglobulin gene rearrangements as MM plasma
cells within the bone marrow and circulation of MM
patients [27-30]. The clinical relevance of these
clonotypic B cells has been unclear, but functional
studies have demonstrated that these cells are
tumorigenic and can give rise to MM plasma cells
both in in vitro colony forming assays as well as
in vivo in immunodeficient nonobese, diabetic,
severe combined deficiency mice [31-33]. Moreover,
clonotypic B cells isolated from the circulation of
MM patients are capable of disease propagation
during serial transplantation studies, demonstrating
that they are capable of self-renewal [33]. Therefore,
MMmay be hierarchically organized and recapitulates
normal plasma cell development. Studies have also
demonstrated that clonotypic B cells are relatively re-
sistant compared with plasma cells to several clinically
utilized antimyeloma agents, including traditional
cytotoxic chemotherapies and novel agents such as
bortezomib and lenalidomide in vitro and in vivo
[33,34].
In addition to cell surface antigen expression, func-
tional flow cytometric assays have been used to identifyclonogenic MM cells. The expression of aldehyde
dehydrogenase is characteristic of normal stem cells
in a variety of adult tissues and can identify CSCs in
both solid tumors and hematologic malignancies
[25]. MM CSCs have been found to express relatively
high levels of aldehyde dehydrogenase with tumori-
genic potential both in vitro and in vivo [33]. The
side population assay takes advantage of differential
emission spectra following exposure to the DNA bind-
ing dye Hoechst 33342 and was initially developed to
identify normal hematopoietic stem cells [35]. This
assay has been used to study MM, and clonogenic
tumor cells have been found to express the side popu-
lation phenotype [33,36]. Further analysis of MM side
population cells has also demonstrated increased
expression of membrane bound drug transporters
(ABCG2 and MDR/Pgp) suggestive of relative drug
resistance [36].
Despite these findings, the existence and precise
phenotype of MM CSCs remains unclear. Studies
examining the B cell nature of tumorigenic MM cells
have demonstrated that these cells lack expression
of the characteristic cell surface antigen CD138
expressed by both normal and MM plasma cells
[33,37]. On the other hand, studies examining MM
side population cells have demonstrated that these
cells are both CD138neg and CD1381 [33,36].
Moreover, the engraftment and growth of primary
MM specimens directly injected into the ectopic
human or rabbit bone fragments implanted into
severe combined immunodeficiency mice (SCID-Hu,
SCID-Rab) is restricted to CD1381MM plasma cells
[38,39]. The reasons for these discrepancies are
unclear, but they likely represent the intrinsic
differences between the animal models or patient
specimens studied, and similar variations in CSC
phenotypes have been observed in several other
human malignancies. An important consideration,
consistent with data emerging now from several lines
of independent research in different malignant and
normal models, is that some surface markers
conventionally associated with the ‘‘stem cell’’
compartment of the tumor cell population may
actually exhibit significant plasticity. Indeed, there is
emerging evidence of substantial bidirectional
interconversions between nonstem and stem-like com-
partments in a population of malignant or normal cells
[36,40-42]. These results provide another possible
explanation for some variations in the observations of
different groups studying the phenotypic features of
putative cancer stem cells. Importantly, the studies on
bidirectional interconversions also indicate the critical
significance of refocusing the investigation on putative
cancer stem cell compartments toward functional
assays, as this may provide a better approach to define
the biologic and clinical implications of cancer cell
populations with stem cell features.
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Given the unique functional attributes of CSCs,
efforts to identify potential targeting strategies are
currently under way. The impact of the tumor micro-
environment on the proliferation and survival of MM
plasma cells has been well documented, and these
interactions have provided the scientific rationale for
specific therapeutic strategies. The influence of the
microenvironment on MM CSCs has recently been
reported, and both the proliferation and relative pro-
portion of side population MM cells can be enhanced
by coincubation with bone marrow stromal cells [36].
Moreover, lenalidomide, but not thalidomide, has
been found to significantly inhibit the number and
colony-forming potential of MM side population cells
associated with alterations in the phosphorylation of
several important signaling molecules including Akt,
GSK-3a/b, MEK1, c-JUN, p53, and p70S6K. These
intriguing results suggest that recent clinical data
demonstrating improved PFS and event-free survival
in patients receiving post-ASCT lenalidomide is medi-
ated by its impact on MM CSCs expressing the side
population phenotype.
Self-renewal appears to be a unique property re-
quired for the maintenance of both normal and cancer
stem cells. The factors regulating MM CSCs are not
fully understood, but the functional similarities be-
tween CSCs and normal stem cells suggest that shared
cellular pathways may be involved. During develop-
ment of the normal embryo, several highly conserved
signaling pathways are required for cell fate specifica-
tion, such as Notch, Wnt, and Hedgehog, and these
have been increasingly implicated in the pathogenesis
of a wide variety of human cancers. Hedgehog signal-
ing has been studied in MM and may have multiple
effects that depend on the precise cell type examined.
In plasma cells, aberrantHedgehog signaling primarily
promotes cell survival, whereas it regulates cell fate de-
cisions of MM CSCs [43,44]. In CD138neg cells,
pathway activation by the Hedgehog ligand induces
self-renewal and cell expansion, whereas the inhibition
by antagonists of SMOOTHENED, a positive regula-
tor of Hedgehog signaling, induces plasma cell
differentiation and the loss of clonogenic potential.
Telomerase may represent another potential means
of targeting MMCSC self-renewal, and a recent study
has reported that the inhibition of telomerase activity
within CD138neg cells using specific inhibitors leads
to decreased tumorigenic potential both in vitro and
in vivo [45]. Therefore, shared self-renewal pathways
may serve as novel therapeutic targets.
The potential of immune-based therapies to target
MM CSCs is evident through the allogeneic graft-
versus-tumor effect that may result in long-term
remissions, and the tumor-specific nature of the M
protein suggests that it may serve as an ideal antigenictarget. A previous study found that the number of
circulating clonotypic B cells was significantly dimin-
ished following vaccination of MM patients with
purifiedM protein [46]. Interestingly, M protein levels
were not significantly altered in these patients, sug-
gesting that this strategy may preferentially target
malignant precursors rather than differentiated plasma
cells. Aberrant expression of the embryonic stem cell–
associated transcription factor SOX2 was initially
identified by screening reactive antibodies present in
patients with monoclonal gammopathy of unknown
significance and may represent another potential
immune target preferentially expressed by MM CSCs
[47]. In monoclonal gammopathy of unknown signifi-
cance, the expression of SOX2 was restricted to
CD138neg cells, and anti-SOX2 immunity limited the
clonogenic growth of primary specimens in vitro.
Tumor-infiltrating lymphocytes may exhibit antitu-
mor activity, and the use of T cells derived from the
bone marrow of MM patients is emerging. These
marrow-infiltrating lymphocytes can be harvested
from the bone marrow, efficiently activated and ex-
panded ex vivo, and safely reinfused in patients with
MM (I.B., personal observation) [48]. Moreover, func-
tional analyses of marrow-infiltrating lymphocytes
have demonstrated that they display greater specificity
for tumor cells than normal peripheral blood lympho-
cytes and are capable of inhibiting both mature plasma
cells and CD138neg CSCs. Thus, immune-based
approaches hold promise as clinically effective MM
CSC targeting strategies.CONCLUSIONS
Evidence for both functional and phenotypic
cellular heterogeneity in MM is emerging. However,
the precise phenotype of tumorigenic MM cells has
not been definitively established and controversy
remains. Whatever their phenotype, it is likely that
definitive proof of the existence of MM CSCs will
be provided by actual improvements in long-term
outcomes using clinical strategies based on CSC
biology rather than further studies of various model
systems. Increasing knowledge of the basic biology of
MM CSCs should produce candidate approaches
that can serve as the basis for novel therapies. The im-
plementation of these strategies into clinical scenarios
that allow MM CSC functions to be assessed, such as
maintenance following tumor debulking by ASCT,
may ultimately provide evidence for their clinical
relevance.ACKNOWLEDGMENT
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